Inhibrx Biosciences, Inc. (INBX) - Total Assets
Based on the latest financial reports, Inhibrx Biosciences, Inc. (INBX) holds total assets worth $146.48 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See how leveraged is Inhibrx Biosciences, Inc.'s balance sheet to measure how much of total assets are equity-financed.
Inhibrx Biosciences, Inc. - Total Assets Trend (2016–2025)
This chart illustrates how Inhibrx Biosciences, Inc.'s total assets have evolved over time, based on quarterly financial data. Check earnings quality score of Inhibrx Biosciences, Inc. to evaluate the quality of earnings relative to operating cash generation.
Inhibrx Biosciences, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Inhibrx Biosciences, Inc.'s total assets of $146.48 Million consist of 90.7% current assets and 9.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 84.8% |
| Accounts Receivable | $177.00K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Inhibrx Biosciences, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see INBX market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Inhibrx Biosciences, Inc.'s current assets represent 90.7% of total assets in 2025, a decrease from 95.9% in 2016.
- Cash Position: Cash and equivalents constituted 84.8% of total assets in 2025, down from 94.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
Inhibrx Biosciences, Inc. Competitors by Total Assets
Key competitors of Inhibrx Biosciences, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Inhibrx Biosciences, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.93 | 3.94 | 4.07 |
| Quick Ratio | 3.93 | 3.94 | 3.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $99.03 Million | $119.67 Million | $85.55 Million |
Inhibrx Biosciences, Inc. - Advanced Valuation Insights
This section examines the relationship between Inhibrx Biosciences, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 245.53 |
| Latest Market Cap to Assets Ratio | 9.39 |
| Asset Growth Rate (YoY) | -19.0% |
| Total Assets | $146.48 Million |
| Market Capitalization | $1.38 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Inhibrx Biosciences, Inc.'s assets at a significant premium (9.39x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Inhibrx Biosciences, Inc.'s assets decreased by 19.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Inhibrx Biosciences, Inc. (2016–2025)
The table below shows the annual total assets of Inhibrx Biosciences, Inc. from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $146.48 Million | -18.97% |
| 2024-12-31 | $180.77 Million | -41.29% |
| 2023-12-31 | $307.89 Million | +5.85% |
| 2022-12-31 | $290.88 Million | +93.34% |
| 2021-12-31 | $150.45 Million | +4.67% |
| 2020-12-31 | $143.74 Million | +442.64% |
| 2019-12-31 | $26.49 Million | +165.31% |
| 2018-12-31 | $9.98 Million | -42.11% |
| 2017-12-31 | $17.25 Million | -18.93% |
| 2016-12-31 | $21.27 Million | -- |
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-bas… Read more